Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-04-18

AUTHORS

Isaac Melguizo-Gavilanes, Janet M. Bruner, Nandita Guha-Thakurta, Kenneth R. Hess, Vinay K. Puduvalli

ABSTRACT

Pseudoprogression (psPD) refers to an increase in size or appearance of new areas of MRI contrast enhancement soon after completing chemoradiation, timely diagnosis of which has been a challenge. Given that tissue sampling of the MRI changes would be expected to accurately distinguish psPD from true progression when MRI changes are first seen, we examined the utility of surgery in diagnosing psPD and influencing patient outcome. We retrospectively reviewed data from adults with GBM who had MRI changes suggestive of progression within 3 months of chemoRT; of these, 34 underwent surgical resection. Three subsets–tumor, psPD or mixed-were identified based on histology and immunohistochemistry in the surgical group and by imaging characteristics in the nonsurgical group. A cohort of patients with stable disease post-chemoRT served as control. PFS and OS were determined using the Kaplan–Meier method and log rank analysis. Concordance for psPD between radiological interpretation and subsequent histological diagnosis was seen in only 32 % of cases (11/34) 95 %CI 19–49 %. A large proportion of patients had a histologically “mixed” pattern with tumor and treatment effect. No significant differences in PFS or OS were seen among the three subtypes. Surgical sampling and histologic review of MRI changes after chemoRT may not serve as a gold standard to distinguish psPD from true progression in GBM patients. Refinement of the histological criteria, careful intraoperative selection of regions of interest and advanced imaging modalities are needed for early differentiation of PsPD from progression to guide clinical management. More... »

PAGES

141-150

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5

DOI

http://dx.doi.org/10.1007/s11060-015-1774-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018898395

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25894594


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemoradiotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Progression", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 75246, Dallas, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.486749.0", 
          "name": [
            "Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 75246, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Melguizo-Gavilanes", 
        "givenName": "Isaac", 
        "id": "sg:person.01013322710.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013322710.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bruner", 
        "givenName": "Janet M.", 
        "id": "sg:person.013375073077.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guha-Thakurta", 
        "givenName": "Nandita", 
        "id": "sg:person.01071535250.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071535250.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hess", 
        "givenName": "Kenneth R.", 
        "id": "sg:person.010260560177.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010260560177.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W, 10th Ave, M410 Staling Loving Hall, 43210, Columbus, OH, USA", 
          "id": "http://www.grid.ac/institutes/grid.261331.4", 
          "name": [
            "Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W, 10th Ave, M410 Staling Loving Hall, 43210, Columbus, OH, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Puduvalli", 
        "givenName": "Vinay K.", 
        "id": "sg:person.01156403355.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156403355.42"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11910-009-0035-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052174107", 
          "https://doi.org/10.1007/s11910-009-0035-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-006-9241-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015983460", 
          "https://doi.org/10.1007/s11060-006-9241-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-009-9897-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030107392", 
          "https://doi.org/10.1007/s11060-009-9897-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10014-012-0109-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012468803", 
          "https://doi.org/10.1007/s10014-012-0109-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-009-9809-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004320007", 
          "https://doi.org/10.1007/s11060-009-9809-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00401-005-0023-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019017045", 
          "https://doi.org/10.1007/s00401-005-0023-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-005-5262-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031267961", 
          "https://doi.org/10.1007/s11060-005-5262-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-007-9341-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000374634", 
          "https://doi.org/10.1007/s11060-007-9341-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-04-18", 
    "datePublishedReg": "2015-04-18", 
    "description": "Abstract\n\nPseudoprogression (psPD) refers to an increase in size or appearance of new areas of MRI contrast enhancement soon after completing chemoradiation, timely diagnosis of which has been a challenge. Given that tissue sampling of the MRI changes would be expected to accurately distinguish psPD from true progression when MRI changes are first seen, we examined the utility of surgery in diagnosing psPD and influencing patient outcome. We retrospectively reviewed data from adults with GBM who had MRI changes suggestive of progression within 3\u00a0months of chemoRT; of these, 34 underwent surgical resection. Three subsets\u2013tumor, psPD or mixed-were identified based on histology and immunohistochemistry in the surgical group and by imaging characteristics in the nonsurgical group. A cohort of patients with stable disease post-chemoRT served as control. PFS and OS were determined using the Kaplan\u2013Meier method and log rank analysis. Concordance for psPD between radiological interpretation and subsequent histological diagnosis was seen in only 32\u00a0% of cases (11/34) 95\u00a0%CI 19\u201349\u00a0%. A large proportion of patients had a histologically \u201cmixed\u201d pattern with tumor and treatment effect. No significant differences in PFS or OS were seen among the three subtypes. Surgical sampling and histologic review of MRI changes after chemoRT may not serve as a gold standard to distinguish psPD from true progression in GBM patients. Refinement of the histological criteria, careful intraoperative selection of regions of interest and advanced imaging modalities are needed for early differentiation of PsPD from progression to guide clinical management.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11060-015-1774-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438826", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2420949", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "123"
      }
    ], 
    "keywords": [
      "MRI changes", 
      "true progression", 
      "utility of surgery", 
      "cohort of patients", 
      "Kaplan-Meier method", 
      "log-rank analysis", 
      "gold standard", 
      "subsequent histological diagnosis", 
      "advanced imaging modalities", 
      "nonsurgical group", 
      "surgical resection", 
      "surgical group", 
      "histological diagnosis", 
      "histologic review", 
      "surgical sampling", 
      "clinical management", 
      "patient outcomes", 
      "timely diagnosis", 
      "histological criteria", 
      "GBM patients", 
      "patients", 
      "intraoperative selection", 
      "radiological interpretation", 
      "progression", 
      "imaging modalities", 
      "chemoRT", 
      "treatment effects", 
      "pseudoprogression", 
      "significant differences", 
      "MRI contrast enhancement", 
      "PSPD", 
      "PFS", 
      "contrast enhancement", 
      "histology", 
      "diagnosis", 
      "cases 95", 
      "rank analysis", 
      "early differentiation", 
      "large proportion", 
      "chemoradiation", 
      "resection", 
      "OS", 
      "surgery", 
      "group", 
      "immunohistochemistry", 
      "cohort", 
      "tumors", 
      "subtypes", 
      "cis-19", 
      "glioblastoma", 
      "months", 
      "outcomes", 
      "adults", 
      "GBM", 
      "modalities", 
      "changes", 
      "tissue", 
      "concordance", 
      "review", 
      "proportion", 
      "differentiation", 
      "management", 
      "differences", 
      "control", 
      "criteria", 
      "appearance", 
      "increase", 
      "standards", 
      "effect", 
      "utility", 
      "patterns", 
      "data", 
      "sampling", 
      "new areas", 
      "analysis", 
      "area", 
      "challenges", 
      "characteristics", 
      "enhancement", 
      "region", 
      "Abstract", 
      "size", 
      "selection", 
      "method", 
      "interest", 
      "characterization", 
      "interpretation", 
      "refinement", 
      "months of chemoRT", 
      "stable disease post-chemoRT", 
      "disease post-chemoRT", 
      "post-chemoRT", 
      "careful intraoperative selection", 
      "Characterization of pseudoprogression"
    ], 
    "name": "Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?", 
    "pagination": "141-150", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018898395"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-015-1774-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25894594"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-015-1774-5", 
      "https://app.dimensions.ai/details/publication/pub.1018898395"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_662.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11060-015-1774-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-015-1774-5'


 

This table displays all metadata directly associated to this object as RDF triples.

306 TRIPLES      22 PREDICATES      147 URIs      131 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-015-1774-5 schema:about N0e9e61a721a246cb99e00f5b4d72be08
2 N3dec1484de3e41c881f7d5ec789c9737
3 N50c9868a24cc491d98f161eb078ea4c5
4 N5cfeeebab6f846baa3405e668a01207b
5 N60eff33490f045ad990c65fbaf802a4b
6 N628cac7c1d344992b6cb2ce72cabb0c6
7 N63ddb40d433d40b9a9a12f32f312775a
8 N6a409d7b4caa434894931369cd85068c
9 N94a55394a4a2421fb4cf217280b91a7d
10 N9ea5303fbf984d6f8e6e9fc42397e5e2
11 Na9f9849837c4471b9fbcaf1b14e4e785
12 Nb7f7a501b34944bebd9e7742596439ba
13 Nc5b80b814e3f4050b643ef7c3c8644e6
14 Nc918a74e946442f8a10e33a1e763b16d
15 Nc98df375c94949c8a29966908289c1b2
16 Ncbbeb50b43954541a70672d362343c0a
17 Ncd19e3c60a394cf7baf3b65ef2603bc9
18 Nd85fda471b964cb9b58dfe27655546bf
19 Nef1c0d1468144af7bee1a45b2ffdd295
20 anzsrc-for:11
21 anzsrc-for:1103
22 schema:author N888f7b1ac3994ce7b8402d0807243927
23 schema:citation sg:pub.10.1007/s00401-005-0023-y
24 sg:pub.10.1007/s10014-012-0109-x
25 sg:pub.10.1007/s11060-005-5262-1
26 sg:pub.10.1007/s11060-006-9241-y
27 sg:pub.10.1007/s11060-007-9341-3
28 sg:pub.10.1007/s11060-009-9809-4
29 sg:pub.10.1007/s11060-009-9897-1
30 sg:pub.10.1007/s11910-009-0035-4
31 schema:datePublished 2015-04-18
32 schema:datePublishedReg 2015-04-18
33 schema:description Abstract Pseudoprogression (psPD) refers to an increase in size or appearance of new areas of MRI contrast enhancement soon after completing chemoradiation, timely diagnosis of which has been a challenge. Given that tissue sampling of the MRI changes would be expected to accurately distinguish psPD from true progression when MRI changes are first seen, we examined the utility of surgery in diagnosing psPD and influencing patient outcome. We retrospectively reviewed data from adults with GBM who had MRI changes suggestive of progression within 3 months of chemoRT; of these, 34 underwent surgical resection. Three subsets–tumor, psPD or mixed-were identified based on histology and immunohistochemistry in the surgical group and by imaging characteristics in the nonsurgical group. A cohort of patients with stable disease post-chemoRT served as control. PFS and OS were determined using the Kaplan–Meier method and log rank analysis. Concordance for psPD between radiological interpretation and subsequent histological diagnosis was seen in only 32 % of cases (11/34) 95 %CI 19–49 %. A large proportion of patients had a histologically “mixed” pattern with tumor and treatment effect. No significant differences in PFS or OS were seen among the three subtypes. Surgical sampling and histologic review of MRI changes after chemoRT may not serve as a gold standard to distinguish psPD from true progression in GBM patients. Refinement of the histological criteria, careful intraoperative selection of regions of interest and advanced imaging modalities are needed for early differentiation of PsPD from progression to guide clinical management.
34 schema:genre article
35 schema:inLanguage en
36 schema:isAccessibleForFree true
37 schema:isPartOf N43dffad5eede4991b6cc7d8b05f907e8
38 Ne42f51e54644468fab49c75665021351
39 sg:journal.1094205
40 schema:keywords Abstract
41 Characterization of pseudoprogression
42 GBM
43 GBM patients
44 Kaplan-Meier method
45 MRI changes
46 MRI contrast enhancement
47 OS
48 PFS
49 PSPD
50 adults
51 advanced imaging modalities
52 analysis
53 appearance
54 area
55 careful intraoperative selection
56 cases 95
57 challenges
58 changes
59 characteristics
60 characterization
61 chemoRT
62 chemoradiation
63 cis-19
64 clinical management
65 cohort
66 cohort of patients
67 concordance
68 contrast enhancement
69 control
70 criteria
71 data
72 diagnosis
73 differences
74 differentiation
75 disease post-chemoRT
76 early differentiation
77 effect
78 enhancement
79 glioblastoma
80 gold standard
81 group
82 histologic review
83 histological criteria
84 histological diagnosis
85 histology
86 imaging modalities
87 immunohistochemistry
88 increase
89 interest
90 interpretation
91 intraoperative selection
92 large proportion
93 log-rank analysis
94 management
95 method
96 modalities
97 months
98 months of chemoRT
99 new areas
100 nonsurgical group
101 outcomes
102 patient outcomes
103 patients
104 patterns
105 post-chemoRT
106 progression
107 proportion
108 pseudoprogression
109 radiological interpretation
110 rank analysis
111 refinement
112 region
113 resection
114 review
115 sampling
116 selection
117 significant differences
118 size
119 stable disease post-chemoRT
120 standards
121 subsequent histological diagnosis
122 subtypes
123 surgery
124 surgical group
125 surgical resection
126 surgical sampling
127 timely diagnosis
128 tissue
129 treatment effects
130 true progression
131 tumors
132 utility
133 utility of surgery
134 schema:name Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?
135 schema:pagination 141-150
136 schema:productId N0f3c62fb9bcb47b1bd5bf26fa022ba24
137 N7f3c6437038943d5b6a660e7978df29b
138 Na18f21855cff40748b67e70bd4eab944
139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018898395
140 https://doi.org/10.1007/s11060-015-1774-5
141 schema:sdDatePublished 2022-01-01T18:36
142 schema:sdLicense https://scigraph.springernature.com/explorer/license/
143 schema:sdPublisher N3d9bed80563a43bfa1e4745c76645c31
144 schema:url https://doi.org/10.1007/s11060-015-1774-5
145 sgo:license sg:explorer/license/
146 sgo:sdDataset articles
147 rdf:type schema:ScholarlyArticle
148 N08a6f371328b4cc8b38e804e074ee359 rdf:first sg:person.013375073077.30
149 rdf:rest N49e9dc70752d43cdbd0282ee213b60bc
150 N0e9e61a721a246cb99e00f5b4d72be08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Prognosis
152 rdf:type schema:DefinedTerm
153 N0f3c62fb9bcb47b1bd5bf26fa022ba24 schema:name dimensions_id
154 schema:value pub.1018898395
155 rdf:type schema:PropertyValue
156 N3d9bed80563a43bfa1e4745c76645c31 schema:name Springer Nature - SN SciGraph project
157 rdf:type schema:Organization
158 N3dec1484de3e41c881f7d5ec789c9737 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Brain Neoplasms
160 rdf:type schema:DefinedTerm
161 N43dffad5eede4991b6cc7d8b05f907e8 schema:volumeNumber 123
162 rdf:type schema:PublicationVolume
163 N49e9dc70752d43cdbd0282ee213b60bc rdf:first sg:person.01071535250.43
164 rdf:rest N501d0b11d26f421cb8a7a18a749005f1
165 N501d0b11d26f421cb8a7a18a749005f1 rdf:first sg:person.010260560177.95
166 rdf:rest N803cf199702344509d6488e4bac00094
167 N50c9868a24cc491d98f161eb078ea4c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Male
169 rdf:type schema:DefinedTerm
170 N5cfeeebab6f846baa3405e668a01207b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Humans
172 rdf:type schema:DefinedTerm
173 N60eff33490f045ad990c65fbaf802a4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Magnetic Resonance Imaging
175 rdf:type schema:DefinedTerm
176 N628cac7c1d344992b6cb2ce72cabb0c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Disease Progression
178 rdf:type schema:DefinedTerm
179 N63ddb40d433d40b9a9a12f32f312775a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Survival Rate
181 rdf:type schema:DefinedTerm
182 N6a409d7b4caa434894931369cd85068c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Immunoenzyme Techniques
184 rdf:type schema:DefinedTerm
185 N7f3c6437038943d5b6a660e7978df29b schema:name doi
186 schema:value 10.1007/s11060-015-1774-5
187 rdf:type schema:PropertyValue
188 N803cf199702344509d6488e4bac00094 rdf:first sg:person.01156403355.42
189 rdf:rest rdf:nil
190 N888f7b1ac3994ce7b8402d0807243927 rdf:first sg:person.01013322710.32
191 rdf:rest N08a6f371328b4cc8b38e804e074ee359
192 N94a55394a4a2421fb4cf217280b91a7d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Female
194 rdf:type schema:DefinedTerm
195 N9ea5303fbf984d6f8e6e9fc42397e5e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Retrospective Studies
197 rdf:type schema:DefinedTerm
198 Na18f21855cff40748b67e70bd4eab944 schema:name pubmed_id
199 schema:value 25894594
200 rdf:type schema:PropertyValue
201 Na9f9849837c4471b9fbcaf1b14e4e785 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Chemoradiotherapy
203 rdf:type schema:DefinedTerm
204 Nb7f7a501b34944bebd9e7742596439ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Adult
206 rdf:type schema:DefinedTerm
207 Nc5b80b814e3f4050b643ef7c3c8644e6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
208 schema:name Biomarkers, Tumor
209 rdf:type schema:DefinedTerm
210 Nc918a74e946442f8a10e33a1e763b16d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Aged
212 rdf:type schema:DefinedTerm
213 Nc98df375c94949c8a29966908289c1b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Glioblastoma
215 rdf:type schema:DefinedTerm
216 Ncbbeb50b43954541a70672d362343c0a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
217 schema:name Neoplasm Staging
218 rdf:type schema:DefinedTerm
219 Ncd19e3c60a394cf7baf3b65ef2603bc9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Middle Aged
221 rdf:type schema:DefinedTerm
222 Nd85fda471b964cb9b58dfe27655546bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
223 schema:name Follow-Up Studies
224 rdf:type schema:DefinedTerm
225 Ne42f51e54644468fab49c75665021351 schema:issueNumber 1
226 rdf:type schema:PublicationIssue
227 Nef1c0d1468144af7bee1a45b2ffdd295 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Young Adult
229 rdf:type schema:DefinedTerm
230 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
231 schema:name Medical and Health Sciences
232 rdf:type schema:DefinedTerm
233 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
234 schema:name Clinical Sciences
235 rdf:type schema:DefinedTerm
236 sg:grant.2420949 http://pending.schema.org/fundedItem sg:pub.10.1007/s11060-015-1774-5
237 rdf:type schema:MonetaryGrant
238 sg:grant.2438826 http://pending.schema.org/fundedItem sg:pub.10.1007/s11060-015-1774-5
239 rdf:type schema:MonetaryGrant
240 sg:journal.1094205 schema:issn 0167-594X
241 1573-7373
242 schema:name Journal of Neuro-Oncology
243 schema:publisher Springer Nature
244 rdf:type schema:Periodical
245 sg:person.01013322710.32 schema:affiliation grid-institutes:grid.486749.0
246 schema:familyName Melguizo-Gavilanes
247 schema:givenName Isaac
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013322710.32
249 rdf:type schema:Person
250 sg:person.010260560177.95 schema:affiliation grid-institutes:grid.240145.6
251 schema:familyName Hess
252 schema:givenName Kenneth R.
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010260560177.95
254 rdf:type schema:Person
255 sg:person.01071535250.43 schema:affiliation grid-institutes:grid.240145.6
256 schema:familyName Guha-Thakurta
257 schema:givenName Nandita
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01071535250.43
259 rdf:type schema:Person
260 sg:person.01156403355.42 schema:affiliation grid-institutes:grid.261331.4
261 schema:familyName Puduvalli
262 schema:givenName Vinay K.
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01156403355.42
264 rdf:type schema:Person
265 sg:person.013375073077.30 schema:affiliation grid-institutes:grid.240145.6
266 schema:familyName Bruner
267 schema:givenName Janet M.
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30
269 rdf:type schema:Person
270 sg:pub.10.1007/s00401-005-0023-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1019017045
271 https://doi.org/10.1007/s00401-005-0023-y
272 rdf:type schema:CreativeWork
273 sg:pub.10.1007/s10014-012-0109-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1012468803
274 https://doi.org/10.1007/s10014-012-0109-x
275 rdf:type schema:CreativeWork
276 sg:pub.10.1007/s11060-005-5262-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031267961
277 https://doi.org/10.1007/s11060-005-5262-1
278 rdf:type schema:CreativeWork
279 sg:pub.10.1007/s11060-006-9241-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1015983460
280 https://doi.org/10.1007/s11060-006-9241-y
281 rdf:type schema:CreativeWork
282 sg:pub.10.1007/s11060-007-9341-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000374634
283 https://doi.org/10.1007/s11060-007-9341-3
284 rdf:type schema:CreativeWork
285 sg:pub.10.1007/s11060-009-9809-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004320007
286 https://doi.org/10.1007/s11060-009-9809-4
287 rdf:type schema:CreativeWork
288 sg:pub.10.1007/s11060-009-9897-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030107392
289 https://doi.org/10.1007/s11060-009-9897-1
290 rdf:type schema:CreativeWork
291 sg:pub.10.1007/s11910-009-0035-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052174107
292 https://doi.org/10.1007/s11910-009-0035-4
293 rdf:type schema:CreativeWork
294 grid-institutes:grid.240145.6 schema:alternateName Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
295 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
296 Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
297 schema:name Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
298 Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
299 Department of Radiology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
300 rdf:type schema:Organization
301 grid-institutes:grid.261331.4 schema:alternateName Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W, 10th Ave, M410 Staling Loving Hall, 43210, Columbus, OH, USA
302 schema:name Division of Neuro-oncology, The Ohio State University Comprehensive Cancer Center, 320 W, 10th Ave, M410 Staling Loving Hall, 43210, Columbus, OH, USA
303 rdf:type schema:Organization
304 grid-institutes:grid.486749.0 schema:alternateName Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 75246, Dallas, TX, USA
305 schema:name Neuro-Oncology Associates at Baylor Charles A. Sammons Cancer Center, 75246, Dallas, TX, USA
306 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...